Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Advanced therapy medicinal products (ATMPs) are beginning to reach European markets, and questions are being asked about their value for patients and how healthcare systems should pay for them. OBJECTIVES: To identify and discuss potential challenges of ATMPs in view of current health technology assessment (HTA) methodology-specifically economic evaluation methods-in Europe as it relates to ATMPs, and to suggest potential solutions to these challenges. METHODS: An Expert Panel reviewed current HTA principles and practices in relation to the specific characteristics of ATMPs. RESULTS: Three key topics were identified and prioritised for discussion-uncertainty, discounting, and health outcomes and value. The panel discussed that evidence challenges linked to increased uncertainty may be mitigated by collection of follow-on data, use of value of information analysis, and/or outcomes-based contracts. For discount rates, an international, multi-disciplinary forum should be established to consider the economic, social and ethical implications of the choice of rate. Finally, consideration of the feasibility of assessing the value of ATMPs beyond health gain may also be key for decision-making. CONCLUSIONS: ATMPs face a challenge in demonstrating their value within current HTA frameworks. Consideration of current HTA principles and practices with regards to the specific characteristics of ATMPs and continued dialogue will be key to ensuring appropriate market access. CLASSIFICATION CODE: I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating patient-based outcome measures for use in clinical trials.
Fitzpatrick, Davey, Buxton, & Jones (1998) · Health Technology Assessment · doi:10.3310/hta2140 · Cited by 1,715
A rational framework for decision making by the National Institute for Clinical Excellence (NICE)
Claxton, K., Sculpher, M., & Drummond, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09832-x · Cited by 456
Health economics and outcomes research within drug development
van Nooten, F., Holmstrom, S., Green, J., Wiklund, I., Odeyemi, I. A. O., & Wilcox, T. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.021 · Cited by 40
Cited by
Berniak-Woźny, J., & Rataj, M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20020908 · Cited by 129
Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
Drummond, M. F., Neumann, P. J., Sullivan, S. D., Fricke, F.-U., Tunis, S., Dabbous, O., & Toumi, M. (2019) · Value in Health · doi:10.1016/j.jval.2019.03.012 · Cited by 92
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J.-M., Greiner, W., Longworth, L., Meunier, A., Moutié, A.-S., Palmer, S., et al. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01212-w · Cited by 71
Reported Challenges in Health Technology Assessment of Complex Health Technologies
Hogervorst, M. A., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022) · Value in Health · doi:10.1016/j.jval.2021.11.1356 · Cited by 37
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“Some argue that other factors may also contribute to the value of ATMPs to patients and society include hope, an unmet need addressed, perceived inno-vativeness and the intervention’s propensity to transform the lives of patients and their carers [78, 85–87].”
Metadata
- Authors
- Jönsson, B., Hampson, G., Michaels, J., Towse, A., von der Schulenburg, J.-M. G., & Wong, O.
- Venue
- The European Journal of Health Economics
- Published
- 2018-09-18
- Volume
- 20
- Issue
- 3
- Pages
- 427-438
- ISSN
- 1439-3972 (ISSN-L)
- 1618-7598
- 1618-7601
- OpenAlex
- W2892087921
- Cited by
- 123
- References
- 3
- FWCI
- 19.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.